Screener
Palvella Therapeutics PVLA Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other income (expense), net | (32) | 224 |
| Loss before income taxes | (15,767) | (8,185) |
| Income tax benefit (expense) | — | — |
| Net loss | $(15,767) | $(8,185) |
| Other comprehensive loss: | ||
| Unrealized gain on investments | 4 | — |
| Foreign currency translation gain (loss) | 8 | (6) |
| Comprehensive loss | $(15,755) | $(8,191) |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's net income?
- Palvella Therapeutics (PVLA) reported net income of -$15.77M in Q1 2026.
- How has Palvella Therapeutics's net income changed year-over-year?
- Palvella Therapeutics's net income decreased by 92.6% year-over-year, from -$8.19M to -$15.77M.
- What is the long-term trend for Palvella Therapeutics's net income?
- Over 4 years (2021 to 2025), Palvella Therapeutics's net income has grown at a -2.3% compound annual growth rate (CAGR), from -$45.74M to -$41.72M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Palvella Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude